Aldosterone synthase inhibition represents an evolving therapeutic advance for hypertension that may complement existing strategies and reshape treatment algorithms pending future trial results.
Aldosterone synthase inhibition represents an evolving therapeutic strategy for hypertension that may complement existing renin-angiotensin-aldosterone-based strategies if future trials confirm cardiovascular and renal benefits.
Absolute Event Rate: 0% vs 0%
Aldosterone synthase inhibition represents an advance in hypertension therapeutics. If ongoing and future outcome-driven trials confirm cardiovascular and renal benefit, ASIs may reshape treatment algorithms, complement existing renin-angiotensin-aldosterone-based strategies, and enable more precise targeting of aldosterone-mediated disease.
Alkhatib et al. (Thu,) reported a other. Aldosterone synthase inhibition represents an evolving therapeutic advance for hypertension that may complement existing strategies and reshape treatment algorithms pending future trial results.